Quantinno Capital Management LP Buys 27,938 Shares of Glaukos Corporation $GKOS

Quantinno Capital Management LP grew its stake in shares of Glaukos Corporation (NYSE:GKOS) by 964.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,836 shares of the medical instruments supplier’s stock after acquiring an additional 27,938 shares during the quarter. Quantinno Capital Management LP’s holdings in Glaukos were worth $3,320,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Stephens Inc. AR bought a new stake in Glaukos in the 1st quarter worth approximately $363,000. DNB Asset Management AS raised its stake in Glaukos by 11.9% during the 4th quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after buying an additional 8,770 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Glaukos by 209.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock valued at $152,476,000 after buying an additional 913,458 shares during the period. Norges Bank bought a new position in shares of Glaukos during the 4th quarter valued at $60,536,000. Finally, Landscape Capital Management L.L.C. boosted its stake in shares of Glaukos by 125.3% in the 4th quarter. Landscape Capital Management L.L.C. now owns 23,017 shares of the medical instruments supplier’s stock worth $2,599,000 after buying an additional 12,799 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Trading Up 5.4%

Shares of GKOS stock opened at $180.24 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company has a market cap of $10.63 billion, a price-to-earnings ratio of -55.46 and a beta of 0.78. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $184.00. The firm has a fifty day moving average price of $144.25 and a 200-day moving average price of $127.19.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.Glaukos’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.24) EPS. As a group, equities analysts predict that Glaukos Corporation will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on GKOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. HC Wainwright raised their target price on Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. BTIG Research boosted their price target on Glaukos from $164.00 to $193.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $177.33.

Insider Transactions at Glaukos

In other news, Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director directly owned 21,092 shares of the company’s stock, valued at $3,535,651.96. The trade was a 2.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 40,525 shares of company stock valued at $6,116,806 over the last quarter. 5.90% of the stock is currently owned by company insiders.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.